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Background: In 2009, a retrospective study reported the detection of xenotropic murine leukemia virus-related virus
(XMRV) in clinical isolates derived from individuals with chronic fatigue syndrome or myalgic encephalomyelitis (CFS).
While many efforts to confirm this observation failed, one report detected polytropic murine leukemia virus (pMLV),
instead of XMRV. In both studies, Polymerase Chain Reaction (PCR)-based methods were employed which could
provide the basis for the development of a practical diagnostic tool. To confirm these studies, we hypothesized that
the ability to detect these viruses will not only depend upon the technical details of the methods employed but also
on the criteria used to diagnose CFS and the availability of well characterized clinical isolates.
Methods: A repository of clinical isolates from geographically distinct sites was generated by the collection of fresh
blood samples from well characterized CFS and healthy subjects. Molecular techniques were used to generate assay
positive controls and to determine the lower limit of detection (LLOD) for murine retroviral and Intracisternal A particle
(Cell 12(4):963-72, 1977) detection methods.
Results: We report the establishment of a repository of well-defined, clinical isolates from five, geographically distinct
regions of the US, the comparative determination of the LLODs and validation efforts for the previously reported
detection methods and the results of an effort to confirm the association of these retroviral signatures in isolates from
individuals with CFS in a blinded, multi-site, prospective study. We detected various, murine retroviral DNA signatures
but were unable to resolve a difference in the incidence of their detection between isolates from CFS (5/72; 6.7%) and
healthy (2/37; 5.4%) subjects (Fisher’s Exact Test, p-value = 1). The observed sequences appeared to reflect the detection
of endogenous murine retroviral DNA, which was not identical to either XMRV or pMLV.
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Conclusions: We were unable to confirm a previously reported association between the detection of XMRV or pMLV
sequences and CFS in a prospective, multi-site study. Murine retroviral sequences were detected at a low frequency
that did not differ between CFS and control subjects. The nature of these sequences appeared to reflect the detection
of pre-existing, endogenous, murine retroviral DNA in the PCR reagents employed.
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The study of CFS suffers from a lack of (i) validated
biomarkers to easily identify the condition and (ii) readily
available, well-defined clinical isolates. Evidence for the
detection of murine leukemia virus (MLV)-related viruses,
including XMRV, in isolates derived from patients with
CFS has been reported [1,2]. The implications of these
findings for patients and the safety of the blood supply
generated a global response from academic, regulatory
and private institutions.
Confirmation of these studies would provide, at the
least, a much needed tool to ease the huge burden associ-
ated with the diagnosis of this disease and enable clinical
trials for the discovery of new treatments. In the period
that followed the original reports, many studies failed to
support a link between CFS and these viruses [3-24].
In this study we also endeavored to confirm a link be-
tween CFS and these viruses, but in a prospective manner
with fresh, well-defined clinical isolates. To enable this
effort, we carefully evaluated the methodologies of the ori-
ginal studies and established the SolveCFS BioBank (SCB);
a patient-centered, advocacy-operated, repository of well-
defined clinical isolates from geographically distinct regions
of the United States. In this blinded, multi-site, prospective
study we were able to detect sequences related to these
viruses. However, we were unable to confirm a difference in
their occurrence between specimens from CFS and healthy
subjects. While we were unsuccessful in confirming the
proposed link, this effort demonstrates the effectiveness
of public/private partnerships in conducting studies of
national scope. Further, the establishment and initial
characterization of the SCB should prove to be a
valuable reference and tool for the future discovery of
CFS-related biomarkers.
Results
Study purpose, design and the establishment of the
SolveCFS Biobank
To confirm reports of an association between CFS and the
detection of murine-related retroviruses, the Chronic
Fatigue and Immune Dysfunction Syndrome (CFIDS)
Association of America, a group of CFS clinical sites and
GlaxoSmithKline (GSK) partnered to conduct a blinded,
multisite, prospective study with well-defined clinicalisolates from a patient advocacy-centered, biological
repository established for this and future studies. The SCB
clinical isolate repository was successfully established with
the collection of blood samples from 240 CFS and 87
healthy subjects from June 2010 to August 2010. Under
the direction of the CFIDs Association coordinator, these
isolates were procured and sent to the Rutgers University
Cell and DNA Repository (RUCDR; Piscataway, NJ) for
processing and storage. Matched health surveys and demo-
graphics were collected for each participant (Table 1).Viral detection assay sensitivity comparisons and
validation
During the effort to seed the SCB with biological speci-
mens, several published methods were evaluated at GSK
for use in this study. These methods involved the direct
detection of viral DNA or RNA by PCR or RT-PCR,
respectively. Positive controls for these assays were estab-
lished to determine each assay’s LLOD. The sensitivity of
the PCR-based methods for the detection of viral DNA
were determined with a serial dilution of a molecular
clone of the viral gag (pXMRV-Gag) prepared in a con-
stant background of DNA purified from healthy, human
peripheral blood mononuclear cells (PBMCs). By this
approach, the LLOD of the PCR-based method to detect
viral DNA described by Lombardi et al. [1] was found to
be approximately 3 copies of viral DNA per 33,000 cell
equivalents (200 ng). Similarly, the LLOD of the PCR-
based method to detect viral DNA described by Lo et al
(Lo Method) [2] was determined to be 5 copies of viral
DNA per 8,250 cell equivalents (50 ng). We also tested the
sensitivity of the method described by Lombardi et al. [1]
to detect viral RNA by RT-PCR. The LLOD for this
method was determined by the use of a serial dilution of
purified gag RNA, prepared from in vitro transcripts by
use of the T7 RNA polymerase promoter in pXMRV-Gag.
Dilutions were prepared in a constant background of RNA
purified from healthy, human PBMCs. By this method, the
LLOD was found to be approximately 3 copies of viral
RNA per 200 ng of total RNA. We also tested the sensitiv-
ity of this method using higher cell equivalent inputs, up
to 2.5 μg per reaction. The LLOD increased as the input
template RNA was increased (data not shown).
Table 1 Demographics, time of CFS-onset, physical health, mental health and clinical site for CFS, healthy and CFS positive control subjects

























Age (years), Mean (STDEV) 50.4 (4.3) 49.4 (12.0) 49.5 (11.6) 30.0 (17.0) 47.6 (14.3) 46.6 (14.8) 28 51.4 (12.5) 50.0 (13.3)
Age of first CFS symptoms (years), Mean (STDEV) 30.6 (13.2) 34.8 (11.4) 34.5 (11.5) NA NA NA 22 34.3 (12.3) 33.5 (12.2)
Age of CFS diagnosis (years), Mean (STDEV) 37.2 (11.3) 38.4 (11.3) 38.3 (11.2) NA NA NA 24 37.1 (9.7) 36.3 (10.0)
Sex, n (%) Female 4 (80) 51 (76) 55 (76) 2 (100) 29 (83) 31 (84) 1 (100) 9 (47) 10 (50)
Male 1 (20) 15 (22) 16 (22) 0 5 (14) 5 (14) 0 7 (37) 7 (35)
Missing data 0 1 (1) 1 (1) 0 1 (3) 1 (3) 0 3 (16) 3 (15)
BMI (kg/m2) Mean (STDEV) 26.2 (5.5) 25.9 (6.0) 25.9 (6.0) 21.2 (2.3) 25.6 (6.0) 25.3 (5.9) 18.6 24.6 (4.6) 24.2 (4.7)
Race, n (%) Caucasian 5 (100) 66 (99) 71 (99) 2 (100) 33 (94) 35 (95) 1 (100) 15 (79) 16 (80)
Non-Caucasian 0 0 0 0 0 0 0 1 (5) 1 (5)
Missing data 0 1 (1) 1 (1) 0 2 (6) 2 (5) 0 3 (16) 3 (15)
CFS Onset, n (%) Gradual 2 (40) 16 (24) 18 (25) NA NA NA 0 8 (42) 8 (40)
Sudden 3 (60) 50 (75) 53 (74) NA NA NA 1 8 (42) 9 (45)
Missing data 0 1 (1) 1 (1) NA NA NA 0 3 (16) 3 (15)
RAND-36 Physical Health Mean (STDEV) Physical functioning 20.0 (14.6) 36.3 (21.1) 35.1 (21.1) 1002 85.0 (30.2) 85.4 (29.8) 5 40.0 (28.3) 38.3 (28.6)
Role-physical 20.0 (44.7) 2.3 (8.5) 3.5 (14.2) 50 90.7 (28.5) 89.6 (28.9) 0 1.3 (5.7) 1.3 (5.6)
Bodily pain 48.0 (22.3) 47.7 (25.1) 47.7 (24.8) 90 84.4 (28.3) 84.6 (27.9) 30 43.8 (24.8) 43.1 (24.3)
General health 24.0 (4.2) 24.9 (16.3) 24.9 (15.8) 90 76.1 (21.2) 76.5 (21.0) 10 15.3 (14.3) 15.0 (14.0)
RAND-36 Mental Health Mean (STDEV) Vitality 12.0 (10.4) 14.7 (13.7) 14.5 (13.4) 55 68.6 (24.8) 68.2 (24.6) 10 17.9 (18.4) 17.5 (18.0)
Social functioning 24.5 (14.5) 28.4 (22.2) 28.1 (21.7) 100 87.2 (26.7) 87.6 (26.4) 0 27.5 (28.1) 26.1 (28.0)
Role emotional 86.7 (29.8) 67.2 (44.7) 68.5 (44.0) 100 86.7 (29.4) 87.0 (29.0) 100 56.1 (44.5) 58.3 (44.4)
Mental health 67.2 (10.0) 60.7 (16.9) 61.2 (16.6) 68 76.1 (26.3) 75.9 (25.9) 64 53.5 (27.0) 54.0 (26.4)
Clinical Site, n (%) Florida 0 6 (9) 6 (8) 0 14 (40) 14 (38) 0 0 0
North Carolina 4 (80) 16 (24) 20 (28) 2 (100) 7 (20) 9 (24) 0 0 0
Pennsylvania 0 1 (1) 1 (1) 0 0 0 0 0 0
Nevada 0 0 0 0 0 0 1 (100) 19 (100) 20 (100)
Utah 1 (20) 44 (66) 45 (63) 0 14 (40) 14 (38) 0 0 0
Data are derived from the RAND-36 Questionnaire and clinical site enrollment and separated into XMRV-positive and XMRV-negative. The majority of subjects were female and all subjects with race reported were Cau-
casian. Subject demographics between CFS subjects and Healthy subjects were similar. CFS subjects had lower physical health and mental health scores compared to Healthy subjects. Statistical comparisons between
XMRV-positive and XMRV-negative categories were not feasible due to sample size limitations.
CFS: chronic fatigue syndrome; XMRV: xenotropic murine leukemia virus-related virus; STDEV: standard deviation; MD: missing data; NA: not applicable; BMI: body mass index: RAND-36: 36-item health-related quality of
life questionnaire.
1Isolates from a 240 CFS (including 40 CFS Positive Control) and 87 healthy subjects were collected. Of these, 72 CFS, 20 CFS Positive Control and 37 healthy subjects were used in this study.
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prospective study, we procured a panel of clinical isolates
from 20 individuals (CFS Positive Control Subjects), self-
reported to have previously received a “XMRV-positive”
test result by a third party. Application of the method for
the detection of viral DNA described by Lombardi et al.
[1] failed to identify any sequence of murine, retroviral
DNA origin in these samples. However, application of the
Lo Method did identify apparent, murine retroviral DNA
in an isolate from one individual (G018) from this panel.
Similarly, application of the method for the detection of
viral RNA described by Lombardi et al. [1] resulted in
the detection of murine, retroviral RNA in an isolate from
one individual (G022) as well (data not shown). We also
attempted a previously reported, pre-amplification by co-
culture approach [25], however, we were unable to resolve
any evidence of murine retroviruses by this method with
plasma samples from the CFS Positive Control Subjects.
Of the two methods in which we were able to detect mur-
ine, retroviral nucleic acid sequences neither appeared to
provide an advantage in sensitivity (i.e. both detected 1
out of 20). As such, we elected to proceed with the Lo
Method for use in our blinded, prospective, multi-site
study as this method required the least amount of material
per test which would allow for the execution of multiple
technical replicates to assess reproducibility of results.
Detection of murine retroviral DNA in both CFS and
healthy subjects
Based upon initial reports of the apparent incidence of
XMRV and pMLV [1,2], we estimated a need to attain
fresh clinical isolates from at least fifty CFS patients with a
CFS to healthy control ratio of about 2:1 (data not shown).
After a sufficient number of isolates had been collected by
the SCB and to begin to satisfy this estimate, an initial set
of isolates from 109 individuals (72 CFS and 37 healthy
subjects) were procured from the SCB for testing at GSK.
The demographics, clinical onset of disease, degree of
physical and mental health, and geographic region associ-
ated with these isolates are detailed in Table 1. Related
statistical analyses are detailed in Additional file 1: Table
S1 and Additional file 2: Table S2 as well as in Additional
file 3: Figure S1. The demographics between the two study
groups were similar (all p-values >0.19, Additional file 1:
Table S1 and Additional file 2: Table S2), as almost all
were derived from Caucasian individuals and most were
female. However, with the exception of role emotional
scale, physical and mental health scores reported by the
CFS subjects were significantly lower than those re-
ported by healthy subjects (Wilcoxon-Mann-Whitney
test; p-values <0.0001).
With the operator blinded to the nature of these iso-
lates, and by the use of the Lo Method, 5 of the 72 iso-
lates derived from CFS subjects (6.9%) and 2 of the 37isolates from healthy subjects (5.4%) resulted in a PCR
positive and DNA sequence confirmed detection of a
murine, retroviral nucleic acid signature. However, no
significant difference in the prevalence of the detection
of these signatures was observed between the CFS and
healthy subject groups (Fisher’s Exact Test, p-value = 1).
Initial analyses to determine the nature of these
sequences indicated that they were distinct from the VP62
and 22Rv1 reference sequences (Table 2) [26,27]. Since
22Rv1 was used to make the pXMRV-gag control, which
was included in every test, the detected sequences did not
arise from this source. In addition, PCR positive signals
were not observed in the negative controls that were
included in each test. Interestingly, a comparison of clones
from each subject revealed some intra-subject diversity.
Differences among these clones included coding changes
in gag, as well as a large in-frame deletion in an isolate
from one CFS subject and a premature stop codon was
detected in an isolate from one healthy subject. These
results suggest that the source of these sequences was
diverse in nature and clearly not clonal or isogenic.
To further characterize these sequences, a phylogenetic
analysis was performed (Figure 1) that included nucleotide
sequences from 7 endogenous, murine retroviral and 13
other related reference strains. The major nodes in the
phylogenetic tree were well-supported by two tree recon-
struction methods, neighbor-joining (NJ) bootstrap and
Bayesian analyses. Strong bootstrap and Bayesian probabil-
ity support for clusters of replicates from individual
subjects was also observed suggesting that the clones were
derived from a common founder event that was distinct to
each subject. All subject amplicons were more closely re-
lated to known clones of murine, endogenous retroviral
sequences (nucleotide diversity as the average number
of net nucleotide substitutions per site between popula-
tions, dA = 0.02201 ± 0.0) than to previously reported
XMRV or pMLV sequences (dA = 0.0386 ± 0. 0.009) [28].
Nearly all sequences from subjects GO53 and G091
were 100% identical to HM990971, which was previ-
ously reported as a contaminant [29]. Among subject
sequences from this study, nucleotide diversity was
slightly higher (π = 0.0057 ± 0.0006) than among previously
published XMRV and pMLV sequences (π = 0.00206 ±
0.00063), suggesting greater sequence variation across our
sample set.
Interestingly, repeat testing of the apparent positives did
not result in the detection of additional, PCR positive re-
sults. Fresh blood redraws from these subjects also did not
result in the detection of any additional murine retroviral
DNA by the Lo Method. Collectively, these results suggest
that the detected sequences exist at a low frequency that is
not robustly detected by the Lo Method.
To determine if the samples and/or reagents harbored
murine DNA, a previously described intracisternal-A
Table 2 XMRV gag amino acid residues 8 to 120 in CFS, CFS positive control and healthy subjects
XMRV gag codon 024 031 032 034 035 036 045 046 047 048 049 050 051 059 060 105
Sample type Sample ID
Published reference VP62 S K K R W V T F N V G W P G V P
Positive control reference 22Rv1 . . . . . . . . . . . . . . I .
CFS positive control subject G018 . R . . . I S I L
CFS subject G026 . R . . . I . . . . . . . S I L
CFS subject G028 . R . . . I . F/S . . . . . S I L
CFS subject G035 . R . . . I . . . . . . . S I L
CFS subject G071 . G . . . V — — — — — — — . I L
CFS subject G091 . R . R/C . I . . . . . . . S I L
Healthy subject G053 . R . . . I . . . . . . . S I L
Healthy subject G046 P R K/E . Stop
Noted along the top are XMRV Gag amino acid residue positions where a difference was observed in one or more subject samples relative to the VP62 reference
virus sequence. Single letter amino acid abbreviations are given for the VP62 reference virus. XMRV gag amino acid residues 8 to 120 in the 22Rv1 positive
control reference virus, one CFS Positive Control Subject, five previously untested CFS Subjects and two Healthy Subjects are displayed. Residues that are identical
to the VP62 reference are denoted by a dot (.), differences are denoted by a single letter amino acid abbreviation, and deletions are denoted by a dash (—).
Healthy Subject G046 has a premature stop codon at residue 35. Also of note, Healthy Subject G053 has a single nucleotide deletion upstream of the Gag start
codon (not shown).
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The sensitivity of this assay was determined with a mo-
lecular clone, pIAP, which was engineered with a 71 base
pair target sequence specific for the primers and probe
and derived from the mouse genome but modified so that
a false negative that may arise from carry over from the
pIAP positive control could be resolved from the wild-
type sequence (see Methods). The LLOD for this method
was determined by serial dilution of pIAP in a background
50 ng of sheared salmon sperm DNA (an unlikely source
of murine genomic DNA) and was observed to be 6 IAP
copies per reaction. Whereas no IAP sequences were de-
tected in the clinical isolates from which murine retroviral
DNA was detected by the Lo Method, low level IAP DNA
(~60 IAP copies in 9 of 9 replicates) was detected in the
Lo Method PCR reagents employed in this study (data
not shown). This observation is similar to the findings
of others [15,29,32-34].
Discussion
Many efforts to confirm the original claim by Lombardi
et al. [1] of an association between the detection of XMRV
and CFS have failed [3-24]. However, one report detected
pMLV, instead of XMRV [2]. In an effort to confirm the
original study and to better understand these collective,
discrepant results, we hypothesized that the ability to
detect these viruses not only depended upon the technical
details of the methods employed but also on the criteria
used to diagnose CFS and the availability of well character-
ized clinical isolates. We elected to compare and attempt
to validate the published methods in a prospective study
with fresh, well defined clinical isolates. The establishment
of the SCB not only provided fresh, well characterized and
geographically distinct samples for our blinded, prospectivestudy, but also made available isolates that could serve as
positive controls for assay validation efforts.
With these fresh samples, we were able to detect mur-
ine, retroviral signatures, however the collective overall
incidence of detection in samples from the validation
and blinded phases of this study was low (5-6.9%). This
inability to robustly detect these sequences was surpris-
ing since the reported incidence was so high [1,2] and
the method employed proved to be highly sensitive in
our hands. The reason for this discrepancy is even less
clear as some reports suggest that the source of the de-
tected retroviral sequences may originate from contam-
ination of the PCR reagents with murine genomic DNA
[15,29]. If this were the source of the observed murine
retroviral sequences, then one might expect that the fre-
quency of detection would be higher for such a sensitive
assay. However, we could not detect these murine, retro-
viral signatures in repeat testing of the same initial sam-
ples after the study was unblinded. We also could not
confirm the detection of murine retroviruses in isolates
from repeat blood draws from subjects in which these
sequences were initially observed in the blinded phase of
this study. Collectively, these results suggest that the
incidence of these detected sequences must be very low;
likely near the LLOD of the assay.
While we did not test for the presence of murine
retrovirus-related antibodies in these subjects, the nature
of the observed sequences appeared to be consistent
with a murine genomic DNA source as evidenced by dir-
ect comparisons at the coding level (Table 2) as well as a
phylogenetic analysis at the nucleotide level (Figure 1).
The observed greater inter- versus intra-subject viral
sequence diversity is consistent with a murine genomic
source and not an individual founder virus or isogenic,
Figure 1 Phylogenetic tree of murine retroviral DNA sequences from CFS and healthy subjects. Results are displayed for one CFS Positive
Control Subject (G018), five CFS Subjects (G026, G028, G035, G071 and G091) and two Healthy Subjects (G046 & G053). For these subjects, the first
four letters/digits are subject anonymous identifier numbers while the last four letters/digits identifies replicates. Public MLV (blue text) and top
mouse clone hits, which are also retroviral homologs (purple text), are included in the tree reconstruction. The position of the previously
reported, PCR XMRV contaminant sequence (HM990971) is indicated [29]. The tree was reconstructed by neighbor-joining (NJ) method using
DNA distance matrices of core conserved nucleotides (see Methods). Asterisks (“*”) indicate those nodes supported 70% or greater in 1000
bootstrap replicate NJ trees and 0.95 Bayesian posterior probability while nodes with numbers had high NJ bootstrap values only. Scale bar
represents 0.1 expected nucleotide substitutions per site.
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firmed by testing for IAP DNA which was observed in the
PCR reagents but not the clinical isolates. We carefully
quantitated the amount of this material at ~30 IAP copies
per unit of Taq DNA polymerase which is much less than
1 murine cell genomic equivalent (~2,000 IAP copies/cell).
It is possible that the amount of this material varies greatly
from batch to batch and that the preparations employed
in the original studies harbored a much higher murine
genomic equivalent [31]. However, it still remains unclear
as to why the previously, published studies did not observean equivalent incidence of these sequences in isolates from
CFS and healthy subjects [1,2].
Although our study inclusion criteria were quite rigor-
ous, subject demographics and sample selection criteria
represent potential constraints for the interpretation of
results from this study. Since a diagnosis of CFS requires
clinical evaluation, this study was designed to work with
clinicians with expertise in CFS diagnosis and manage-
ment. However, it is known that patients in tertiary care
clinics, such as those tested in this study, are not strictly
representative of the general CFS patient population and
Irlbeck et al. BMC Research Notes 2014, 7:461 Page 7 of 10
http://www.biomedcentral.com/1756-0500/7/461are more likely to be Caucasian, female, and more severely
ill [35]. Despite this, the results of this study are consistent
with those of another prospective confirmation effort [19]
and the SCB should prove to be a valuable resource for
the discovery of CFS-related biomarkers and treatments in
future studies.
Conclusions
The results of this blinded, multi-site, prospective study are
consistent with those of other confirmation studies. Spe-
cifically, using previously published PCR-based detection
methods, we found no difference in the incidence of detect-
able murine retroviral sequences in the PBMC DNA from
well characterized CFS and healthy subjects. In addition,
our results suggest that the Taq DNA polymerase that was
used in the PCR detection method was the source of the
murine retroviral signatures observed in isolates from both
the CFS and healthy subjects tested in this study. CFS rep-
resents a major unmet medical need and additional studies
are needed to determine the etiology of the syndrome so
that effective treatments may be discovered.
Methods
Establishment of the “SolveCFS Biobank” clinical
repository
The initial seeding of the SCB clinical repository, led by
the CFIDS Association of America, was achieved by the
collection of blood samples from a total of 240 CFS and
87 healthy subjects in three months (June to August
2010). Subjects were selected from five, geographically
distinct clinical sites that specialized in the diagnosis and
management of CFS. Of these, 83 CFS and 55 healthy sub-
jects were enrolled by a Utah-based clinic, 74 CFS and 8
healthy subjects by a clinic in North Carolina, 43 CFS and
24 healthy subjects by a Florida-based clinic, 1 CFS subject
by a clinic in Pennsylvania and 40 CFS subjects who had
tested positive for XMRV prior to this study (CFS Positive
Controls) by a Nevada-based clinical site. The latter were
intended to serve as clinical positive controls for use in de-
tection method validation. The 87 healthy subject samples
collected were from individuals who were geographically
co-localized (same neighborhood or region; but not re-
siding in the same household or of close relation to a CFS
subject) and were matched to the CFS subjects by age
(within 5 years), sex, and race. After receipt of informed
consent, the SCB coordinator assigned each participant a
unique identifier and arranged for the completion of a
questionnaire by mail aimed at resolving details relevant
for the consideration of inclusion in the study.
Sample collection, processing and storage
Each clinical site was provided with blood collection kits
that included four, 10 mL sodium-heparin, Vacutainer™
tubes (Becton Dickinson; Franklin Lakes, NJ) and returnshipping materials by the SCB. The collection and process-
ing methods were similar to those defined in the study by
Lombardi et al. 2009. Blood was collected into the SCB-
provided collection tubes by venipuncture using standard
phlebotomy procedures and shipped overnight by express
mail at ambient temperature to the RUCDR for processing.
PBMCs were processed by the standard operating proce-
dures of the RUCDR. The collection tubes were centrifuged
at 1,200 × g at room temperature to separate plasma and
cells. After collection of plasma, the remaining PBMC band
was purified by density gradient centrifugation at 800 × g
for 22 minutes after layering on NycoPrep™ (Axis Shield,
PoC, Oslo, Norway). Purified PBMCs were aspirated and
washed once with Dulbecco’s phosphate-buffered saline
(Life Technologies, Carlsbad, CA). Dry and TRIzol (Life
Technologies; Carlsbad, CA)-resuspended cell pellets of 10
million cells each were prepared by centrifugation at 500 ×
g for 7 minutes and stored at -80°C. An additional 10 mil-
lion cells were cryopreserved in 90% FBS and 10% DMSO
and stored in liquid nitrogen. Dry and TRIzol cell pellets
were shipped to GSK for DNA and RNA isolation and sub-
sequent viral detection methods. For all subjects with a
positive result for the detection of MLV-related sequences,
a subsequent separate blood sample was collected and dry
and TRIzol cell pellets were prepared and shipped to GSK
as described above.
Subject population
A CFS subject was eligible for inclusion in this study if
they had previously been diagnosed with CFS by either
the Fukuda or the Canadian criteria [36,37], in addition
to having initial presentation of flu-like illness or an
acute (48 hours) or subacute (4 weeks) onset; fatigue that
persisted for at least six months; post-exertional malaise
lasting >24 hours; significant cognitive impairment in
short-term memory and concentration; RAND-36 quality
of life survey [38-40] results that meet 2 of the 3 following
benchmarks: vitality <35, social functioning <62.5, role-
physical <50; and age between 18 and 65 years at the time
of signing the informed consent.
Female subjects were eligible to participate if not preg-
nant, not <3 months postpartum, and not currently lactat-
ing per self-report. A subject was excluded if they had a
body mass index >40, an immunosuppressive disorder in-
cluding, but not limited to cancer, severe infections or HIV.
In addition, subjects were excluded if they had a history of
substance or alcohol abuse < 2 years before onset of CFS or
were mentally or legally incapacitated at the time of collec-
tion. De-identified registry data was provided to GSK for
verification prior to receipt of isolates for study.
Isolation of nucleic acid from clinical isolates
DNA was extracted and purified from dry cell pellets by
silica-based adsorption with a QIAamp DNA Blood Mini
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separate cell pellets by guanidinium thiocyanate-phenol-
chloroform extraction using the TRIzol reagent by Life
Technologies (Carlsbad, CA). Yield and purity for nucleic
acid preparations was determined by UV spectroscopy
with a NanoDrop spectrophotometer (NanoDrop Prod-
ucts; Wilmington, DE).
Positive controls for PCR detection methods
A positive control for XMRV was created by TOPO TA
cloning (Life Technologies, Carlsbad CA) PCR amplified
XMRV gag DNA products from 22RV1 cells using the
previously described 419F and 1154R primers. Plasmid
DNA was purified with a PureLink HiPure Plasmid
Maxiprep Kit (Life Technologies; Carlsbad, CA) and quan-
tified by UV spectroscopy with a NanoDrop Spectropho-
tometer. The cloned gag insert was sequence verified and
found to be identical to XMRV-VP62 (GenBank accession
number EF185282.1) with the exception of a guanine to
adenine substitution at position 367 relative to the 5′ end
of the 419F primer. An IAP containing plasmid, pIAP, was
created in a pUC57 backbone by GenScript (Piscataway,
NJ). The 71 base pair IAP sequence (5′-GCCGC GCCCA
CATTC GCCGT TACAA GATGG TGCTG ACTCG
ACAGT TCTAA GTGGT AAACA AATAA TCTGC
G-3′), was derived from the murine genome and designed to
be recognized by the primers and probe from a previously
described method. To enable the resolution of false from
real IAP-positive PCR detection, 6 nucleotides situated
between the probe and downstream primer sequence were
changed to their complementary base (italicized). The
resulting sequence is not 100% homologous to any known
sequence of the mouse genome and, as such, would be
easily resolved by sequencing. This would allow reso-
lution of whether an IAP positive sample was contami-
nated with material of mouse origin or from the assay
positive control.
PCR-Based XMRV and IAP detection assays
PCR primers were synthesized by Integrated DNA Tech-
nologies (Coralville, IA). For the XMRV DNA detection
method described by Lombardi et al., 200 ng of subject
DNA (~33,000 cell equivalents) was amplified using the
gag 419F and 1154R primers as described [1]. For the
XMRV DNA detection method described by Lo et al.
(Lo Method), 50 ng of subject DNA (~8,250 cell equiva-
lents) was employed and tested as described [2]. The
IAP assay was as described by Shin et al. [15]. For all
PCR-based detection methods, products were resolved
by agarose gel electrophoresis using 15 μL of the PCR
reaction. PCR products that migrated in the gel to a size
that was within approximately 150 base pairs of each
assay’s respective positive control were extracted from
the gel, purified using the MinElute Gel Extraction Kit(Qiagen; Valencia, CA) and cloned with a TOPO TA
Cloning Kit (Life Technologies; Carlsbad, CA). Cloned
DNA was purified with the PureLink Quick Plasmid
Miniprep Kit (Life Technologies; Carlsbad, CA), and se-
quenced by Sanger chain-terminating dideoxynucleotide
sequencing (Life Technologies; Carlsbad, CA). If at least
1 clone was identified with >95% sequence identity by
BLASTN [41] searches of GenBank (Nonredundant or
nr database version February 2011) to published XMRV
or MLV-related sequences, the individual was considered
positive for harboring XMRV/MLV-related viral DNA.
DNA sequences are available from NCBI (GenBank
Accession# KM222449 -> KM222492).
Statistical analyses
Demographics as well as Physical and Mental Health data
(Table 1) were analyzed using SAS 9.2 (SAS Institute,
Cary, NC). Figures were created in JMP 11.0 (SAS Insti-
tute, Cary, NC). We were interested in the following
comparisons: CFS Subjects vs. Healthy Subjects, CFS
Subjects vs. CFS Positive Control Subjects, and Healthy
Subjects vs. CFS Positive Control Subjects. Comparing
XMRV Positive versus XMRV Negative Subjects within
or between groups was not feasible due sample size limita-
tions. The continuity-corrected Wilcoxon-Mann-Whitney
test was used for all continuous variables. The normal
approximations statistic Z and the two sided p-values are
provided in the Additional file 1: Table S1. Fisher’s exact
test was used for all categorical variables, and the results
are provided in Additional file 2: Table S2. Missing data
were not included in the statistical analyses.
Phylogenetic analysis
Initial multiple sequence alignments of the conserved
region of the gag gene were performed using the program
CLUSTALW v1.83 [42] with default settings and sub-
sequently, refined manually using the program SEQLAB
of the GCG Wisconsin Package v11.0 software package
(Accelrys, San Diego, CA, USA). A final alignment 339 nu-
cleotides in length was used for all subsequent phylogen-
etic analyses. We constructed phylogenetic trees using
distance NJ and Bayesian posterior probabilities (BP). NJ
trees were based on pair wise distances between nucleic
acid sequences using the programs NEIGHBOR and DNA-
DIST (Dayhoff option) of the PHYLIP 3.6 package [43].
The programs SEQBOOT and CONSENSE were used to
estimate the confidence limits of branching points from
1000 bootstrap replications. BP trees were constructed
using the software MrBayes v3.0B4 [44,45]. The gamma-
distributed rate model with 6 discrete rate categories (GTR
model) was chosen. Markov chains were run for 106 gener-
ations, burn-in values were set for 104 generations, and
trees sampled every 100 generations. All trees were visual-
ized using the program TREEVIEW v1.6.6 [46]. Nucleotide
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average number of net nucleotide substitutions per site
between populations (dA) was calculated using the software
DnaSPv5 [47].Ethical approval
The subjects who participated in this study gave in-
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the study were conducted in conformity with the ethical
guidelines of the Declaration of Helsinki. The protocol
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Additional file 1: Table S1. Statistical Comparisons of CFS, Healthy and
CFS Positive Control Subjects for Demographics, Physical and Mental
Health. Demographics, physical and mental health data were analyzed
comparing CFS Subjects vs. Healthy Subjects, CFS Subjects vs. CFS
Positive Control Subjects, and Healthy Subjects vs. CFS Positive Control
Subjects. The continuity-corrected Wilcoxon-Mann-Whitney test was used
for all continuous variables. The normal approximations statistic Z and
the two sided p-values are provided for each comparison. CFS Subjects
and CFS Positive Control Subjects exhibited significantly lower physical
and mental health scores when compared to those reported by the
Healthy Subjects.
Additional file 2: Table S2. Statistical Comparisons of CFS, CFS Positive
Control and Healthy Subjects for Sex, Race, CFS Onset and XMRV Status.
Fisher’s exact test results comparing CFS vs. Healthy Subjects, CFS vs. CFS
Positive Control Subjects, and Healthy vs. CFS Positive Control Subjects
for Sex, Race, CFS Onset and XMRV Status. No significant difference in the
prevalence of murine, retroviral nucleic acid signatures (XMRV Positive
and Negative Status) was observed between the CFS and Healthy Subject
groups.
Additional file 3: Figure S1. Physical and Mental Health and
Demographics for CFS, CFS Positive Control and Healthy Subjects. Scatter
plots of a. RAND-36 physical health scores, b. RAND-36 mental health
scores and c. demographics of CFS Subjects, Healthy Subjects and CFS
Positive Control Subjects. Subjects with a positive test result for XMRV/
murine retroviral sequences as a result of testing in this report are
indicated by a cross (x) and subjects with a negative XMRV test result are
indicated by a filled circle (●). Mean values for each subject group are
indicated by a dash (–).Abbreviations
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